FORT LEE, N.J., Sept. 19, 2012 /PRNewswire/ -- Herborium
Group, Inc., (OTC Pink: HBRM) www.herborium.com, a Botanical
Therapeutics® Company is pleased to announce that it has now
commenced the repurchase of the Company's common shares . "We have
now commenced our share buyback program which was announced on
April 23, 2012. After review of our
strong 3rd quarter revenues along with the rapidly increasing
orders of AcnEase® and enthusiastic response to Kamasutra™ Spirit
with our proprietary blend of exotic herbs, that are being
processed for the 4th quarter we have decided that this gives us
the financial opportunity to repurchase up to 100 million shares
which process begun and will continue in this 4th Quarter to the
end of 2012," stated Dr. Agnes P.
Olszewski Chairwoman and CEO of Herborium. "Thanks to our
very successful social media marketing strategy, a demand for
AcnEase®, our unique all botanical acne treatment targeting over
120 million acne sufferers in the US and Europe, has been up for the 3rd consecutive
Quarter with sales up over 20% yet again. The Company is
anticipating to continue its growth in 4th Quarter making 2012 not
only a very successful sales year, but the beginning of a new phase
for the future. The 4Th Quarter of 2012 is also the time
when the Company is to launch its unique Botanical Therapeutics®
for Sexual Health for Women and Men, and its all botanical
ingredients based healthy Energy formula. Together with an
introduction of Kamasutra™ we are indeed on the road to build a
much larger Herborium as we enter new avenues for the use of our
product," concluded Dr. Olszewski.
With the anticipated continuous growth that the Company expects
to capture in 2013 financial projections forecast Herborium is
currently in the process of taking steps of becoming a fully
reporting, audited Public Entity at some point in 2013.
About Herborium Group, Inc.
Herborium Group, Inc., a Botanical Therapeutics® company,
focuses on developing, licensing, and marketing proprietary,
botanical based medicinal products to consumers and healthcare
professionals. The Company uses clinical validation to establish
and maintain a differential advantage. The company sells its
products in the US and Europe. For
more information, please visit www.herborium.com and
www.acnease.com.
One of our most important responsibilities is to communicate
with shareholders in an open and direct manner. Comments are based
on current management expectations, and are considered
"forward-looking statements," generally preceded by words such as
"plans," "expects," "believes," "anticipates," or "intends." We
cannot promise future returns. Our statements reflect our best
judgment at the time, and we disclaim any obligation to update or
alter forward-looking statements as the result of new information
or future events. The Company urges investors to review the risks
and uncertainties contained within its filings with the OTC Markets
and/or Securities and Exchange Commission.
For more information please inquire:
Investorsrelations@herborium.com
SOURCE Herborium Group, Inc.